Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Bayer
Femme et Homme Max 99 ans
Bayer AG
MAJ Il y a 5 ans
Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities
To evaluate whether rivaroxaban added to acetylsalicylic acid (ASA) is superior to ASA alone in reducing the risk of major thrombotic vascular events (defined as myocardial infarction (MI), ischemic s...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bayer Schering Pharma Oy
MAJ Il y a 5 ans
Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age
The main objective of this study is to assess the safety and efficacy of 2 doses of LNG, delivered locally by a new intrauterine contraceptive system suitable for use by women 18 to 35 years of age.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Freistaat Bayern, vertreten durch die Universität Regensburg
MAJ Il y a 5 ans
Die perioperative Anwendung von Etoricoxib verglichen mit Diclofenac bei Patienten nach Implantation einer Hüftgelenkstotalendoprothese, prospektive, doppelt blinde Phase IIIb Studie
It will be analyzed whether the use of Etoricoxib as compared to Diclofenac leads to a reduction of the perioperative risk of bleedings. The primary objective of the study is the designation of the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer AG
MAJ Il y a 5 ans
Rivaroxaban for treatment in venous thrombosis in children
The primary efficacy objective is: To assess the incidence of symptomatic recurrent venous thromboembolism The principal safety objective is: To assess the incidence of overt major and clinica...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer AG
MAJ Il y a 5 ans
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
Demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular mortality and morbidity in subjects with type 2 diabe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer PLC (UK)
MAJ Il y a 5 ans
Rivaroxaban in Antiphospholipid Syndrome (RAPS)
Background and study aims Antiphospholipid syndrome (APS), in patients with or without lupus, causes blood clots (thrombosis); any blood vessel in the body is at risk but most commonly a deep vein thr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer Schering Pharma AG (BSP)
MAJ Il y a 5 ans
Multi-center, randomized comparison study to eVALUatE outcomes and resource needs of imaging and treatment following Primovist-enhanced MRI of the liver in comparison to extracellular contrast media (ECCM)-enhanced MRI and contrast-enhanced computed tomography (CT) in patients with a history of colorectal cancer and known or suspected metachronous liver metastases
The main objective of this study is to evaluate outcomes and resource needs of imaging and treatment following Primovist-enhanced MRI (PV-MRI) as compared to ECCM-enhanced MRI (ECCM-MRI) and contrast-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Study to research BAY 1021189 in patients with worsening heart failure with reduced ejection fraction Studio di Fase IIb sulla sicurezza ed efficacia di quattro regimi posologici di BAY 1021189 in pazienti con HfrEF affetti da insufficienza cardiaca cronica in via di peggioramento (SOCRATES-REDUCED)
To find the optimal dose of BAY 1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment by characterizing the safety, tolerability, pharmacodynamic effects, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A multicenter Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy En multicenter fas III okontrollerad öppen prövning för att utvärdera säkerheten och effekten av BAY 81-8973 hos barn med svår hemofili A enligt profylax behandling
The primary objective is to evaluate the safety and efficacy of the treatment with BAY 81-8973 for prophylaxis and treatment of breakthrough bleeds in children with haemophilia A
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Exploring the efficacy of once daily oral rivaroxaban for treatment of thrombus in left atrial/left atrial appendage in subjects with nonvalvular atrial fibrillation or atrial flutter Ocena skuteczności rywaroksabanu podawanego doustnie jeden raz na dobę, w leczeniu skrzepliny w lewym przedsionku / uszku lewego przedsionka u pacjentów z migotaniem przedsionków niezwiązanym z wadą zastawkową lub u pacjentów z trzepotaniem przedsionków
The primary objective of the study is to explore the effect of rivaroxaban on the complete resolution of LA/LAA thrombi at the end-of-treatment visit (after 6 weeks of treatment) in subjects with no...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
11
Suivant